Clinical Trials
16 trialsNCT06117085 2024-11-21
CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules
Pulse Biosciences, Inc.
Phase NA Completed
NCT05600322 2024-10-03
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Photocure
Phase 3 Completed
NCT04192565 2024-09-19
A Prospective Investigation of the ColubrisMX ELS System
ColubrisMX
Phase NA Completed
NCT04667689 2024-04-01
CAMPFIRE
University of Rochester
Phase NA Completed
NCT01701284 2023-11-18
rTMSinCP
Northwestern University
Phase NA Completed
NCT04257799 2022-06-22
Lumpectomy Specimen Margin Evaluation With Tomography and Structured Light Imaging
Dartmouth-Hitchcock Medical Center
Completed
NCT02690805 2021-04-19
Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System
University of California, Irvine
Completed
NCT01851772 2021-01-12
Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer
Xoft, Inc.
Phase NA Completed
NCT01373671 2020-08-07
DBT
Siemens Medical Solutions USA - CSG
Phase NA Completed
NCT02828865 2020-07-07
A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers
National Taiwan University Hospital
Phase NA Completed
NCT02841436 2020-07-07
A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer
National Taiwan University Hospital
Phase NA Completed
NCT03215992 2018-08-02
Optical Tomography in Prostate Cancer
Columbia University
Phase NA Completed
NCT01078415 2016-11-08
Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
Angiodynamics, Inc.
Phase NA Completed
NCT01369420 2016-11-08
NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer
Angiodynamics, Inc.
Phase 2 Completed
NCT01236300 2016-06-08
INSPECT
University of Chicago
Phase NA Completed
NCT00431561 2013-12-03
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
Isarna Therapeutics GmbH
Phase 2 Completed